Deinove completes key milestone in its Deinochem program

By Deinove | June 15, 2016

Deinove, an industrial biotech company developing innovative processes for producing biofuels and biobased compounds by using Deinococcus bacteria as host strains, recently announced that it has validated the second key milestone of the Deinochem program, dedicated to the production of biosourced isoprenoids, funded by ADEME (French Environment and Energy Management Agency) in the framework of the “Investments for the Future” program launched by the French government.

The Deinochem program aims to develop methods for producing compounds of industrial interest from renewable resources by optimizing the natural performance of Deinococcus bacteria. The first target molecules are part of the isoprenoid family (including carotenoids) that may lead to the production of specialty ingredients, such as antioxidants and / or high-added value pigments, representing a market of hundreds of millions of dollars worldwide in applications such as cosmetics, food, feed and health.

"The Deinochem program progresses according to plan and in line with the expectations of ADEME, but also with those of industrial partners," says Emmanuel Petiot, CEO of Deinove. "The tools we have implemented as part of this project clearly open up very promising opportunities in new areas of specialty chemicals with high-added value."

The Deinove teams are currently working on developing bacterial strains that are hyperproductive of carotenoids by fermentation. After a first key step focused on optimizing the construction of modified strains1, this second step has led to significant progress in:

Sequencing and annotation of a hundred strains, which led to the identification of genes of interest and the establishment of a comprehensive collection of "Deinobricks": DNA fragments that can be used for strain optimization;

Strengthening the fermentation capabilities (x10) through acquisition of new equipment and the development of data processing software. Now 32 different fermentation conditions can be tested in parallel.

Achievement of targeted production yields up to five times greater than that of the wild strain, demonstrating the commercial viability of the process.

According to the aid agreement signed in 20132, validation by ADEME of achievement of deliverables associated with the 2nd key milestone triggers the payment of approximately € 1.5 million ($1.69 million) of repayable advances, expected by the end of June 2016.